TruSpine Technologies PLC Further re Bridge Loan Facility (5894O)
01 Fevereiro 2023 - 7:23AM
UK Regulatory
TIDMTSP
RNS Number : 5894O
TruSpine Technologies PLC
01 February 2023
1 February 2023
TruSpine Technologies plc
("TruSpine" or the "Company")
Further re Bridge Loan Facility
TruSpine Technologies Plc, the medical device company focused on
the spinal (vertebral) stabilisation market, provides an update in
relation to the announcement made on 3 January 2023 concerning the
Bridge Loan and LOI entered into with the Investment Group to
provide the Company with staged equity funding.
The GBP200,000 Bridge Loan transfer has experienced delays,
however the Company and the Investment Group anticipate that the
funds of the Bridge Loan will be received shortly by the Company
and the subscription for Tranche 1 is expected to be subscribed for
on or before 17 February 2023.
The Company continues to carefully manage its working capital. A
further announcement will be made in due course.
Capitalised terms used in this announcement shall, unless
otherwise defined, have the same meanings as set out in the
Company's announcement of 3 January 2023.
This announcement contains inside information for the purposes
of the UK Market Abuse Regulation, and the Directors of the Company
are responsible for the release of this announcement.
Enquiries:
TruSpine Technologies Plc Tel: +44 (0)20 3638 5025
Ian Roberts, CEO
Cairn Financial Advisers LLP (AQSE Corporate Adviser) Tel: +44 (0)20 7213 0880
Liam Murray / Ludovico Lazzaretti
Oberon Capital (Joint Broker) Tel: +44 (0)20 3179 5300
Mike Seabrook / Chris Crawford
Peterhouse Capital Limited (Joint Broker & Financial Adviser)
Tel: +44 (0)20 7469 0930
Lucy Williams / Duncan Vasey
Walbrook PR (Financial PR & IR) Tel: +44 (0) 20 7933 7870 or +44 (0) 7876 741 001
Anna Dunphy truspine@walbrookpr.com
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identi ed by their use of terms and phrases such as "believe",
"could", "should" "envisage", "estimate", "intend", "may", "plan",
"potentially", "expect", "will" or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward-looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. The
stated parameters of the planned agreement between the Company and
Spartan Medical, Inc. do not necessarily represent a final,
legally-binding contract. Such forward looking statements re ect
the Directors' current beliefs and assumptions and are based on
information currently available to the Directors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NEXTBMMTMTTMBBJ
(END) Dow Jones Newswires
February 01, 2023 05:23 ET (10:23 GMT)
TruSpine Technologies (AQSE:TSP)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
TruSpine Technologies (AQSE:TSP)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025
